Viral hepatitis is a worldwide disease particularly the incidence of chronic viral hepatitis B in China is at the top in the world. Hepatitis B and C will develop to chronic hepatitis and about 20% of them will develop as cirrhosis, 1-5% will develop as hepatocarcinoma after 10 to 20 years of progress. There are about 30 million chronic hepatitis in China at present which is hazardous for the society. Although many drugs have been used in the treatment of chronic viral hepatitis, no satisfied drug is available because of the low therapeutic efficacy, higher rebound rate after withdrawal treatment as well as higher price and side effects. So, developing newly effective, safe and relatively cheaper anti-hepatitis drug is very necessary.
|